https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-17 / J Clin Oncol 33, 2015 (suppl; abstr e13030)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-17 / J Clin Oncol 33, 2015 (suppl; abstr e13030)2015-06-17 12:08:122019-07-17 12:08:33Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-17 / Front Oncol 2015;5:98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-17 / Front Oncol 2015;5:982015-06-17 00:00:002021-11-15 13:27:21Brain Tumor Immunotherapy: What have We Learned so Far?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-13 / J. Neurooncol. 2015 Sep;124(2):325-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-13 / J. Neurooncol. 2015 Sep;124(2):325-322015-06-13 00:00:002021-11-15 13:28:49Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-02 / Front Immunol 2015;6:271
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-02 / Front Immunol 2015;6:2712015-06-02 00:00:002015-06-02 00:00:00Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr 2036)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr 2036)2015-06-01 12:02:252019-07-17 12:02:49Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr TPS9082)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr TPS9082)2015-06-01 11:35:202019-07-17 11:35:43Phase III multicenter trial of eltrapuldencel-T: Autologous dendritic cells loaded with irradiated autologous tumor cells (DC-TC) in granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma (INTUS trial).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr 7007)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr 7007)2015-05-30 00:00:002021-08-09 07:52:34Long-term follow-up of patients with acute myelogenous leukemia receiving an autologous telomerase-based dendritic cell vaccine.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr TPS5070)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr TPS5070)2015-05-30 00:00:002015-05-30 00:00:00Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr 3048)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr 3048)2015-05-30 00:00:002015-05-30 00:00:00Phase II randomized trial of autologous tumor lysate dendritic cell vaccine (ADC) plus best supportive care (BSC) compared with BSC, in pre-treated advanced colorectal cancer patients.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-29 / J Clin Oncol 33, 2015 (suppl; abstr e14033)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-29 / J Clin Oncol 33, 2015 (suppl; abstr e14033)2015-05-29 00:00:002015-05-29 00:00:00A study of mature alpha-DC-1 vaccine to induce immune responses in ovarian cancer.
